Global Hip Osteoarthritis Pain Drug Market Research Report 2021

Publisher Name :
Date: 12-Jan-2021
No. of pages: 123
Inquire Before Buying

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

- Oral

- Injection

- External

Segment by Application

- Medical Care

- Personal Care

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

By Company

- Pfizer

- Johnson and Johnson

- GlaxoSmithKline

- Bayer

- Eli Lilly

- Novartis

- Sanofi

- Horizon Pharma

- Abbott

- Mylan

- Daiichi Sankyo

- TEVA

- Almatica Pharma

- Astellas Pharma

- Tide Pharmaceutical

- Iroko Pharmaceuticals

- Hengrui Pharmaceutical

- Abiogen Pharma

Global Hip Osteoarthritis Pain Drug Market Research Report 2021

Table of Contents
1 Hip Osteoarthritis Pain Drug Market Overview
1.1 Product Overview and Scope of Hip Osteoarthritis Pain Drug
1.2 Hip Osteoarthritis Pain Drug Segment by Type
1.2.1 Global Hip Osteoarthritis Pain Drug Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Oral
1.2.3 Injection
1.2.4 External
1.3 Hip Osteoarthritis Pain Drug Segment by Application
1.3.1 Hip Osteoarthritis Pain Drug Sales Comparison by Application: (2021-2027)
1.3.2 Medical Care
1.3.3 Personal Care
1.4 Global Hip Osteoarthritis Pain Drug Market Size Estimates and Forecasts
1.4.1 Global Hip Osteoarthritis Pain Drug Revenue 2016-2027
1.4.2 Global Hip Osteoarthritis Pain Drug Sales 2016-2027
1.4.3 Hip Osteoarthritis Pain Drug Market Size by Region: 2016 Versus 2021 Versus 2027
2 Hip Osteoarthritis Pain Drug Market Competition by Manufacturers
2.1 Global Hip Osteoarthritis Pain Drug Sales Market Share by Manufacturers (2016-2021)
2.2 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Hip Osteoarthritis Pain Drug Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Hip Osteoarthritis Pain Drug Manufacturing Sites, Area Served, Product Type
2.5 Hip Osteoarthritis Pain Drug Market Competitive Situation and Trends
2.5.1 Hip Osteoarthritis Pain Drug Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Hip Osteoarthritis Pain Drug Players Market Share by Revenue
2.5.3 Global Hip Osteoarthritis Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hip Osteoarthritis Pain Drug Retrospective Market Scenario by Region
3.1 Global Hip Osteoarthritis Pain Drug Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Hip Osteoarthritis Pain Drug Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Hip Osteoarthritis Pain Drug Market Facts & Figures by Country
3.3.1 North America Hip Osteoarthritis Pain Drug Sales by Country
3.3.2 North America Hip Osteoarthritis Pain Drug Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Hip Osteoarthritis Pain Drug Market Facts & Figures by Country
3.4.1 Europe Hip Osteoarthritis Pain Drug Sales by Country
3.4.2 Europe Hip Osteoarthritis Pain Drug Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Hip Osteoarthritis Pain Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales by Region
3.5.2 Asia Pacific Hip Osteoarthritis Pain Drug Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Hip Osteoarthritis Pain Drug Market Facts & Figures by Country
3.6.1 Latin America Hip Osteoarthritis Pain Drug Sales by Country
3.6.2 Latin America Hip Osteoarthritis Pain Drug Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Hip Osteoarthritis Pain Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Hip Osteoarthritis Pain Drug Sales by Country
3.7.2 Middle East and Africa Hip Osteoarthritis Pain Drug Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Hip Osteoarthritis Pain Drug Historic Market Analysis by Type
4.1 Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2016-2021)
4.2 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2016-2021)
4.3 Global Hip Osteoarthritis Pain Drug Price by Type (2016-2021)
5 Global Hip Osteoarthritis Pain Drug Historic Market Analysis by Application
5.1 Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2016-2021)
5.2 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2016-2021)
5.3 Global Hip Osteoarthritis Pain Drug Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Pfizer Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Johnson and Johnson
6.2.1 Johnson and Johnson Corporation Information
6.2.2 Johnson and Johnson Description and Business Overview
6.2.3 Johnson and Johnson Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Johnson and Johnson Product Portfolio
6.2.5 Johnson and Johnson Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.3.4 GlaxoSmithKline Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Corporation Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Bayer Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Corporation Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Eli Lilly Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Novartis Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Sanofi Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Horizon Pharma
6.8.1 Horizon Pharma Corporation Information
6.8.2 Horizon Pharma Description and Business Overview
6.8.3 Horizon Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Horizon Pharma Product Portfolio
6.8.5 Horizon Pharma Recent Developments/Updates
6.9 Abbott
6.9.1 Abbott Corporation Information
6.9.2 Abbott Description and Business Overview
6.9.3 Abbott Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Abbott Product Portfolio
6.9.5 Abbott Recent Developments/Updates
6.10 Mylan
6.10.1 Mylan Corporation Information
6.10.2 Mylan Description and Business Overview
6.10.3 Mylan Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Mylan Product Portfolio
6.10.5 Mylan Recent Developments/Updates
6.11 Daiichi Sankyo
6.11.1 Daiichi Sankyo Corporation Information
6.11.2 Daiichi Sankyo Hip Osteoarthritis Pain Drug Description and Business Overview
6.11.3 Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Daiichi Sankyo Product Portfolio
6.11.5 Daiichi Sankyo Recent Developments/Updates
6.12 TEVA
6.12.1 TEVA Corporation Information
6.12.2 TEVA Hip Osteoarthritis Pain Drug Description and Business Overview
6.12.3 TEVA Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.12.4 TEVA Product Portfolio
6.12.5 TEVA Recent Developments/Updates
6.13 Almatica Pharma
6.13.1 Almatica Pharma Corporation Information
6.13.2 Almatica Pharma Hip Osteoarthritis Pain Drug Description and Business Overview
6.13.3 Almatica Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Almatica Pharma Product Portfolio
6.13.5 Almatica Pharma Recent Developments/Updates
6.14 Astellas Pharma
6.14.1 Astellas Pharma Corporation Information
6.14.2 Astellas Pharma Hip Osteoarthritis Pain Drug Description and Business Overview
6.14.3 Astellas Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Astellas Pharma Product Portfolio
6.14.5 Astellas Pharma Recent Developments/Updates
6.15 Tide Pharmaceutical
6.15.1 Tide Pharmaceutical Corporation Information
6.15.2 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Description and Business Overview
6.15.3 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Tide Pharmaceutical Product Portfolio
6.15.5 Tide Pharmaceutical Recent Developments/Updates
6.16 Iroko Pharmaceuticals
6.16.1 Iroko Pharmaceuticals Corporation Information
6.16.2 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Description and Business Overview
6.16.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Iroko Pharmaceuticals Product Portfolio
6.16.5 Iroko Pharmaceuticals Recent Developments/Updates
6.17 Hengrui Pharmaceutical
6.17.1 Hengrui Pharmaceutical Corporation Information
6.17.2 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Description and Business Overview
6.17.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Hengrui Pharmaceutical Product Portfolio
6.17.5 Hengrui Pharmaceutical Recent Developments/Updates
6.18 Abiogen Pharma
6.18.1 Abiogen Pharma Corporation Information
6.18.2 Abiogen Pharma Hip Osteoarthritis Pain Drug Description and Business Overview
6.18.3 Abiogen Pharma Hip Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Abiogen Pharma Product Portfolio
6.18.5 Abiogen Pharma Recent Developments/Updates
7 Hip Osteoarthritis Pain Drug Manufacturing Cost Analysis
7.1 Hip Osteoarthritis Pain Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Hip Osteoarthritis Pain Drug
7.4 Hip Osteoarthritis Pain Drug Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Hip Osteoarthritis Pain Drug Distributors List
8.3 Hip Osteoarthritis Pain Drug Customers
9 Hip Osteoarthritis Pain Drug Market Dynamics
9.1 Hip Osteoarthritis Pain Drug Industry Trends
9.2 Hip Osteoarthritis Pain Drug Growth Drivers
9.3 Hip Osteoarthritis Pain Drug Market Challenges
9.4 Hip Osteoarthritis Pain Drug Market Restraints
10 Global Market Forecast
10.1 Hip Osteoarthritis Pain Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Hip Osteoarthritis Pain Drug by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Hip Osteoarthritis Pain Drug by Type (2022-2027)
10.2 Hip Osteoarthritis Pain Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Hip Osteoarthritis Pain Drug by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Hip Osteoarthritis Pain Drug by Application (2022-2027)
10.3 Hip Osteoarthritis Pain Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Hip Osteoarthritis Pain Drug by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Hip Osteoarthritis Pain Drug by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Hip Osteoarthritis Pain Drug Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Hip Osteoarthritis Pain Drug Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Hip Osteoarthritis Pain Drug Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Hip Osteoarthritis Pain Drug Covered in This Study
Table 5. Global Hip Osteoarthritis Pain Drug Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Hip Osteoarthritis Pain Drug Sales Share by Manufacturers (2016-2021)
Table 7. Global Hip Osteoarthritis Pain Drug Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Hip Osteoarthritis Pain Drug Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Hip Osteoarthritis Pain Drug Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Hip Osteoarthritis Pain Drug Manufacturing Sites and Area Served
Table 11. Manufacturers Hip Osteoarthritis Pain Drug Product Type
Table 12. Global Hip Osteoarthritis Pain Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Hip Osteoarthritis Pain Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hip Osteoarthritis Pain Drug as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Hip Osteoarthritis Pain Drug Sales by Region (2016-2021) & (K Units)
Table 16. Global Hip Osteoarthritis Pain Drug Sales Market Share by Region (2016-2021)
Table 17. Global Hip Osteoarthritis Pain Drug Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Hip Osteoarthritis Pain Drug Sales by Country (2016-2021) & (K Units)
Table 19. North America Hip Osteoarthritis Pain Drug Sales Market Share by Country (2016-2021)
Table 20. North America Hip Osteoarthritis Pain Drug Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Hip Osteoarthritis Pain Drug Revenue Market Share by Country (2016-2021)
Table 22. Europe Hip Osteoarthritis Pain Drug Sales by Country (2016-2021) & (K Units)
Table 23. Europe Hip Osteoarthritis Pain Drug Sales Market Share by Country (2016-2021)
Table 24. Europe Hip Osteoarthritis Pain Drug Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Hip Osteoarthritis Pain Drug Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Hip Osteoarthritis Pain Drug Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Hip Osteoarthritis Pain Drug Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Hip Osteoarthritis Pain Drug Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Hip Osteoarthritis Pain Drug Revenue Market Share by Region (2016-2021)
Table 30. Latin America Hip Osteoarthritis Pain Drug Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Hip Osteoarthritis Pain Drug Sales Market Share by Country (2016-2021)
Table 32. Latin America Hip Osteoarthritis Pain Drug Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Hip Osteoarthritis Pain Drug Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Hip Osteoarthritis Pain Drug Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Hip Osteoarthritis Pain Drug Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Hip Osteoarthritis Pain Drug Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Hip Osteoarthritis Pain Drug Revenue Market Share by Country (2016-2021)
Table 38. Global Hip Osteoarthritis Pain Drug Sales (K Units) by Type (2016-2021)
Table 39. Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2016-2021)
Table 40. Global Hip Osteoarthritis Pain Drug Revenue (Million US$) by Type (2016-2021)
Table 41. Global Hip Osteoarthritis Pain Drug Revenue Share by Type (2016-2021)
Table 42. Global Hip Osteoarthritis Pain Drug Price (USD/Unit) by Type (2016-2021)
Table 43. Global Hip Osteoarthritis Pain Drug Sales (K Units) by Application (2016-2021)
Table 44. Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2016-2021)
Table 45. Global Hip Osteoarthritis Pain Drug Revenue (Million US$) by Application (2016-2021)
Table 46. Global Hip Osteoarthritis Pain Drug Revenue Share by Application (2016-2021)
Table 47. Global Hip Osteoarthritis Pain Drug Price (USD/Unit) by Application (2016-2021)
Table 48. Pfizer Corporation Information
Table 49. Pfizer Description and Business Overview
Table 50. Pfizer Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Pfizer Hip Osteoarthritis Pain Drug Product
Table 52. Pfizer Recent Developments/Updates
Table 53. Johnson and Johnson Corporation Information
Table 54. Johnson and Johnson Description and Business Overview
Table 55. Johnson and Johnson Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Johnson and Johnson Hip Osteoarthritis Pain Drug Product
Table 57. Johnson and Johnson Recent Developments/Updates
Table 58. GlaxoSmithKline Corporation Information
Table 59. GlaxoSmithKline Description and Business Overview
Table 60. GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. GlaxoSmithKline Hip Osteoarthritis Pain Drug Product
Table 62. GlaxoSmithKline Recent Developments/Updates
Table 63. Bayer Corporation Information
Table 64. Bayer Description and Business Overview
Table 65. Bayer Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Bayer Hip Osteoarthritis Pain Drug Product
Table 67. Bayer Recent Developments/Updates
Table 68. Eli Lilly Corporation Information
Table 69. Eli Lilly Description and Business Overview
Table 70. Eli Lilly Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Eli Lilly Hip Osteoarthritis Pain Drug Product
Table 72. Eli Lilly Recent Developments/Updates
Table 73. Novartis Corporation Information
Table 74. Novartis Description and Business Overview
Table 75. Novartis Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Novartis Hip Osteoarthritis Pain Drug Product
Table 77. Novartis Recent Developments/Updates
Table 78. Sanofi Corporation Information
Table 79. Sanofi Description and Business Overview
Table 80. Sanofi Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Sanofi Hip Osteoarthritis Pain Drug Product
Table 82. Sanofi Recent Developments/Updates
Table 83. Horizon Pharma Corporation Information
Table 84. Horizon Pharma Description and Business Overview
Table 85. Horizon Pharma Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 86. Horizon Pharma Hip Osteoarthritis Pain Drug Product
Table 87. Horizon Pharma Recent Developments/Updates
Table 88. Abbott Corporation Information
Table 89. Abbott Description and Business Overview
Table 90. Abbott Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Abbott Hip Osteoarthritis Pain Drug Product
Table 92. Abbott Recent Developments/Updates
Table 93. Mylan Corporation Information
Table 94. Mylan Description and Business Overview
Table 95. Mylan Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Mylan Hip Osteoarthritis Pain Drug Product
Table 97. Mylan Recent Developments/Updates
Table 98. Daiichi Sankyo Corporation Information
Table 99. Daiichi Sankyo Description and Business Overview
Table 100. Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 101. Daiichi Sankyo Hip Osteoarthritis Pain Drug Product
Table 102. Daiichi Sankyo Recent Developments/Updates
Table 103. TEVA Corporation Information
Table 104. TEVA Description and Business Overview
Table 105. TEVA Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 106. TEVA Hip Osteoarthritis Pain Drug Product
Table 107. TEVA Recent Developments/Updates
Table 108. Almatica Pharma Corporation Information
Table 109. Almatica Pharma Description and Business Overview
Table 110. Almatica Pharma Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 111. Almatica Pharma Hip Osteoarthritis Pain Drug Product
Table 112. Almatica Pharma Recent Developments/Updates
Table 113. Astellas Pharma Corporation Information
Table 114. Astellas Pharma Description and Business Overview
Table 115. Astellas Pharma Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 116. Astellas Pharma Hip Osteoarthritis Pain Drug Product
Table 117. Astellas Pharma Recent Developments/Updates
Table 118. Tide Pharmaceutical Corporation Information
Table 119. Tide Pharmaceutical Description and Business Overview
Table 120. Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 121. Tide Pharmaceutical Hip Osteoarthritis Pain Drug Product
Table 122. Tide Pharmaceutical Recent Developments/Updates
Table 123. Iroko Pharmaceuticals Corporation Information
Table 124. Iroko Pharmaceuticals Description and Business Overview
Table 125. Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 126. Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Product
Table 127. Iroko Pharmaceuticals Recent Developments/Updates
Table 128. Hengrui Pharmaceutical Corporation Information
Table 129. Hengrui Pharmaceutical Description and Business Overview
Table 130. Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 131. Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Product
Table 132. Hengrui Pharmaceutical Recent Developments/Updates
Table 133. Abiogen Pharma Corporation Information
Table 134. Abiogen Pharma Description and Business Overview
Table 135. Abiogen Pharma Hip Osteoarthritis Pain Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 136. Abiogen Pharma Hip Osteoarthritis Pain Drug Product
Table 137. Abiogen Pharma Recent Developments/Updates
Table 138. Production Base and Market Concentration Rate of Raw Material
Table 139. Key Suppliers of Raw Materials
Table 140. Hip Osteoarthritis Pain Drug Distributors List
Table 141. Hip Osteoarthritis Pain Drug Customers List
Table 142. Hip Osteoarthritis Pain Drug Market Trends
Table 143. Hip Osteoarthritis Pain Drug Growth Drivers
Table 144. Hip Osteoarthritis Pain Drug Market Restraints
Table 145. Global Hip Osteoarthritis Pain Drug Sales Forecast by Type (2022-2027) & (K Units)
Table 146. Global Hip Osteoarthritis Pain Drug Sales Market Share Forecast by Type (2022-2027)
Table 147. Global Hip Osteoarthritis Pain Drug Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 148. Global Hip Osteoarthritis Pain Drug Revenue Market Share Forecast by Type (2022-2027)
Table 149. Global Hip Osteoarthritis Pain Drug Sales Forecast by Application (2022-2027) & (K Units)
Table 150. Global Hip Osteoarthritis Pain Drug Sales Market Share Forecast by Application (2022-2027)
Table 151. Global Hip Osteoarthritis Pain Drug Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 152. Global Hip Osteoarthritis Pain Drug Revenue Market Share Forecast by Application (2022-2027)
Table 153. Global Hip Osteoarthritis Pain Drug Sales Forecast by Region (2022-2027) & (K Units)
Table 154. Global Hip Osteoarthritis Pain Drug Sales Market Share Forecast by Region (2022-2027)
Table 155. Global Hip Osteoarthritis Pain Drug Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 156. Global Hip Osteoarthritis Pain Drug Revenue Market Share Forecast by Region (2022-2027)
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Hip Osteoarthritis Pain Drug
Figure 2. Global Hip Osteoarthritis Pain Drug Market Share by Type in 2020 & 2027
Figure 3. Oral Product Picture
Figure 4. Injection Product Picture
Figure 5. External Product Picture
Figure 6. Global Hip Osteoarthritis Pain Drug Market Share by Application in 2020 & 2027
Figure 7. Medical Care
Figure 8. Personal Care
Figure 9. Global Hip Osteoarthritis Pain Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Hip Osteoarthritis Pain Drug Market Size 2016-2027 (US$ Million)
Figure 11. Global Hip Osteoarthritis Pain Drug Sales 2016-2027 (K Units)
Figure 12. Global Hip Osteoarthritis Pain Drug Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 13. Hip Osteoarthritis Pain Drug Sales Share by Manufacturers in 2020
Figure 14. Global Hip Osteoarthritis Pain Drug Revenue Share by Manufacturers in 2020
Figure 15. The Global 5 and 10 Largest Hip Osteoarthritis Pain Drug Players: Market Share by Revenue in 2020
Figure 16. Hip Osteoarthritis Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 17. Global Hip Osteoarthritis Pain Drug Sales Market Share by Region (2016-2021)
Figure 18. Global Hip Osteoarthritis Pain Drug Sales Market Share by Region in 2020
Figure 19. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region (2016-2021)
Figure 20. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region in 2020
Figure 21. U.S. Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 22. Canada Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Germany Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. France Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. U.K. Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Italy Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Russia Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. China Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Japan Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. South Korea Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. India Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Australia Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Taiwan Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Indonesia Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Thailand Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Malaysia Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Philippines Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Vietnam Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Mexico Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Brazil Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Argentina Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Turkey Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Saudi Arabia Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. UAE Hip Osteoarthritis Pain Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Sales Market Share of Hip Osteoarthritis Pain Drug by Type (2016-2021)
Figure 46. Sales Market Share of Hip Osteoarthritis Pain Drug by Application (2016-2021)
Figure 47. Sales Market Share of Hip Osteoarthritis Pain Drug by Application in 2020
Figure 48. Revenue Share of Hip Osteoarthritis Pain Drug by Application (2016-2021)
Figure 49. Revenue Share of Hip Osteoarthritis Pain Drug by Application in 2020
Figure 50. Manufacturing Cost Structure of Hip Osteoarthritis Pain Drug
Figure 51. Manufacturing Process Analysis of Hip Osteoarthritis Pain Drug
Figure 52. Hip Osteoarthritis Pain Drug Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs